UC San Diego researchers describe the underlying signaling pathway that results in pulmonary arterial hypertension and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formation characterizing the disease.
Related Articles

News
UC San Diego Helps Expand Parkinson’s Progression Markers Initiative
December 6, 2021
sandiegobiotech
News
Comments Off on UC San Diego Helps Expand Parkinson’s Progression Markers Initiative
UC San Diego School of Medicine partners with The Michael J. Fox Foundation on a clinical study to identify biomarkers of Parkinson’s disease. The study seeks to recruit 4,000 participants by the end of 2023. Click here to view original post… […]

News
Using Everyday WiFi To Help Robots See and Navigate Better Indoors
May 20, 2022
sandiegobiotech
News, UCSD News
Comments Off on Using Everyday WiFi To Help Robots See and Navigate Better Indoors
UC San Diego engineers have developed a low cost, low power technology to help robots accurately map their way indoors, even in poor lighting and without recognizable landmarks or features. The technology uses W… […]

News
Three UC San Diego Engineering Professors Receive Presidential Early Career Awards
July 3, 2019
sandiegobiotech
News
Comments Off on Three UC San Diego Engineering Professors Receive Presidential Early Career Awards